Keyword: Bristol Myers Squibb
BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.
Giovanni Caforio, CEO of Bristol Myers Squibb, oversaw one of the biggest transformations in the company’s history—its $74 billion acquisition of Celgene.
It’s been a long road for Opdivo, but the immuno-oncology star finally has a place in the lucrative market for previously untreated NSCLC.
After getting the cold shoulder from regulators for its ide-cel filing, BMS at least has good news this week for one product it acquired with Celgene.
With a median follow-up of 8.1 months, the combination of Opdivo, Yervoy and two cycles of chemo had cut the risk of death by 31%.
Just days away from an FDA decision, the company’s Opdivo-Yervoy combo has put up positive three-year data in non-small cell lung cancer.
The FDA cited manufacturing problems in refusing to review Bristol Myers' submission for a CAR-T cell therapy developed with bluebird.
COVID-19-related stocking boosted BMS' first quarter, but the pandemic is limiting access to oncology clinics, putting pressure on drugs like Opdivo.
BMS and Exelixis boast a potential kidney cancer contender—but they’ll have to meet a “high bar” to gain market traction, one analyst says.
BMS' Opdivo-Yervoy combo is awaiting big decisions in non-small cell lung cancer, but in the meantime, it’s making its mark in a smaller indication.